0 Items
Select Page

Legionella

The bacterium L. pneumophila was first identified in 1977, as the cause of an outbreak of severe pneumonia in a convention centre in the USA in 1976. It has since been associated with outbreaks linked to poorly maintained artificial water systems, particularly cooling towers or evaporative condensers associated with air conditioning and industrial cooling, hot and cold water systems in public and private buildings, and whirlpool spas.

 

Our monoclonal antibodies and native antigen can be used in support of assay development and R&D into Legionella infection. We also provide a novel system for species-specific detection and labeling of L. pneumophila which can be used with a range of tags for purification and microscopic imaging.

Legionella background

L. pneumophila is an opportunistic intracellular pathogen that was first recognised in a group of individuals, presenting with a lung infection, who had attended a convention in Philadelphia in 1976. It is the causative agent of a severe type of pneumonia referred to as Legionnaires’ disease. The symptoms of Legionnaires’ disease include shortness of breath, cough, headache, fever and muscle ache, which can occur 2 – 10 days after exposure. Complications associated with infection may result in death. L. pneumophila may also cause a mild form of disease known as Pontiac fever, which is self-limiting and doesn’t require hospitalisation (CDC). Both forms of the disease may also be referred to as Legionellosis.

Legionella Antigens

We are pleased to offer a native extract of inactivated Legionella pneumophila antigen taken from culture. No vaccine is currently available for legionellosis and it is hoped that these reagents will enable the research community to develop new serological assays and vaccine candidates for future use.

Legionella Immunoassays

The Native Antigen Company are pleased to provide both ELISA assays and chemical reporters which can be used for detection of Legionella phneumophila.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Why We Need New Diagnostics for the Zika Virus

This article has been published in Volume 2, Issue 3 of the IBI journal.While Zika is no longer in the public eye, it hasn’t vanished. Recent outbreaks across Asia and Africa are reminders that Zika is alive and well, and with no effective countermeasures...

Clostridium difficile Toxins: The Nuts and Bolts

In this blog, we describe the mechanisms of action of the Clostridium difficile A and B toxins, and discuss their use in research and medicine. The Native Antigen Company provides biologically active C. diff toxins, as well as inactivated toxoids for a range of...

Where Are We At with CMV Vaccine Development?

In this blog, we discuss the need for a CMV vaccine, the current vaccine strategies that are in development, and introduce our range of CMV antigens and antibodies.Cytomegalovirus The human Cytomegalovirus (CMV) is an enveloped, icosahedral 150-200nm pleomorphic...

Paper Synopsis: Measles Induces Immune Amnesia

In the midst of widespread concern about growing anti-vaccination sentiments, worldwide, a study published this month suggests that Measles virus infection can also ablate acquired immunity to other diseases. In this blog, we introduce the concept of immune amnesia,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 3 =

Live Customer Feedback

Join our mailing list

* indicates required